NRG/RTOG 0415 late toxicity tolerance doses
ForLow-risk prostate cancer, HRT arm of NRG/RTOG 0415
TL;DRRectal D5% (EQD2) ≤62 Gy predicted halving late ≥G2 GI toxicity from 20% to 10% after 70 Gy at 2.5 Gy/fx in low-risk prostate cancer.
The constraint that matters is a small-volume hotspot, not the high-dose V74Gy rule, which 16% of plans missed anyway. Pts with acute GI toxicity have a lower modeled tolerance (D5% ≤55 Gy for a 10% late GI rate), so planning targets may need to differ by acute course. Bladder dose explained nothing for GU, pointing elsewhere for mitigation.
In low-risk prostate cancer planned for moderate HRT at 2.5 Gy/fx, this supports adding a rectal D5% (EQD2) ceiling near 62 Gy as a GI-toxicity planning goal; it does not inform GU toxicity, where no bladder dose-response emerged.
The constraint that matters is a small-volume rectal hotspot (D5%), not the V74Gy rule that 16% of plans missed anyway. Pts with acute GI toxicity carry lower modeled tolerance (D5% ≤55 Gy for a 10% late GI rate), and bladder dose explained nothing for GU, pointing mitigation toward substructures.
11 details 1 trial watching
Secondary dose-volume analysis of the HRT arm of the multicenter NRG/RTOG 0415 trial, N=521. Cohort split 70%/30% into training and validation with preserved toxicity rates; univariate and multivariate logistic regression on bootstrapping.
Low-risk prostate cancer treated on the HRT arm. Median follow-up 5.9 yr.
70 Gy at 2.5 Gy/fraction, 3DCRT/IMRT N=108/413. Doses converted to EQD2 with rectum α/β 3 Gy and bladder 6 Gy; trial rectal constraint EQD2 74 Gy ≤15%.
Late ≥G2 GI and GU toxicity, plus proctitis and pollakiuria (the symptoms with rates ≥10%). Generalizability required validation AUC within training AUC ± SD, p≤0.05, and pHL >0.05.
Rectal D5% was the dominant GI predictor; with or without acute GI toxicity it generalized (AUCvalidation 0.64, 0.65). Modeled late GI falls from 20% to 10% at D5% ≤62 Gy. No GU dose-response was found, including at α/β 0.8 Gy.
| Late GI rate | D5% (Model IV) | D5% if acute GI tox (Model II) |
|---|---|---|
| 20% (observed) | 65 Gy | ≤59 Gy |
| 15% | ≤64 Gy | ≤58 Gy |
| 10% | ≤62 Gy | ≤55 Gy |
PROFIT, CHHiP, HYPRO and RTOG 0415 established moderate HRT with similar biochemical control to CFRT but a tendency to more late toxicity. The late GI rate here was 19% vs 2% in a cited high-dose CFRT IMRT series planned with a strict high-dose rectal constraint.
Validation is an internal random split of the same cohort, not an external dataset. The IMRT-heavy mix (79% vs 21%) left a technique interaction untestable, and constraint adherence was incomplete, so part of the signal may reflect plan quality rather than tolerance.
Results point to small rectal hotspots as the modifiable driver of excess late GI toxicity after moderate HRT, with authors also advocating rectal spacers. GU toxicity likely needs a substructure (not whole-bladder) approach.
Post-hoc NTCP modeling within one arm of a phase III; modest AUC 0.64-0.65, internal split validation only, no prospective test of the proposed D5% constraint.
- Does a prospective D5% ≤62 Gy rectal objective lower late GI toxicity?
- Which urinary substructure drives late GU toxicity after HRT?
- Does rectal spacer use make the D5% threshold redundant? n=500 · primary completion 2027-12 · SpaceOAR Vue effect on late GI toxicity, prostate SBRT
📚 Sources · 📄 1 paper
The longer read
The HRT trials that moved prostate practice toward moderate hypofractionation, PROFIT, CHHiP, HYPRO and RTOG 0415 among them, settled the efficacy question but left a toxicity residue: late GI and GU events tended to run higher than with conventional fractionation, and in RTOG 0415 the difference reached significance for both domains. The obvious response is better normal-tissue constraints, yet most constraints in use were inherited from conventional schedules. This analysis is one of the few attempts to derive HRT-specific rectal tolerance from prospectively collected trial toxicity, which is its main value.
The finding that matters is where the risk sits in the DVH. The parent trial already carried a high-dose rectal volume constraint, but the model points at the minimum dose to the hottest 5% of rectum rather than the intermediate-dose volumes or the protocol's V74 rule. That is consistent with a hotspot mechanism, and it is clinically convenient: a D5% objective is easy to add to an IMRT optimizer without rewriting the whole constraint set. The other practical point is that adherence to the existing rectal constraint was incomplete, lower still among pts who developed toxicity. Some of the excess late GI risk after HRT may therefore be a plan-quality problem rather than a fractionation problem, and a new number will not fix plans that do not meet the old one.
Confidence should be tempered by the statistics. Discrimination is modest, with validation AUCs of 0.64 and 0.65, which means D5% explains only a fraction of who gets late GI toxicity. Validation was an internal random split of the same 521 pts, so the model was tested on pts planned under the same protocol, the same contouring rules and the same era of IMRT; that is generalizability within a trial, not across practice. The proctitis model only approached significance in validation. The predicted halving of toxicity at D5% 62 Gy is a model extrapolation along a fitted logistic curve over a narrow dose range, not an observed effect of lowering the dose, and the cohort is dominated by IMRT, so any technique effect is unresolved.
The acute-toxicity interaction deserves more attention than it gets. Pts with acute GI toxicity had considerably lower modeled thresholds, which, if real, suggests either individual radiosensitivity or a consequential-late mechanism, and in either case argues that a single constraint is too blunt. It does not yet tell a planner what to do before treatment starts, since acute toxicity is not known at planning.
The null GU result is informative. Late GU toxicity was more common than GI, yet whole-bladder dose explained none of it even with a much lower α/β. That supports looking at urinary substructures rather than tightening bladder constraints. What the analysis cannot answer is whether a D5% objective, applied prospectively and combined with spacers, actually lowers late GI toxicity after moderate HRT; that would require an external or prospective test, and the paper offers none. It is a reasonable, low-cost planning objective to consider, not a validated tolerance.